Very very promising (and for Β£800k)28 Jan 2025 00:02
Results from Phase 2 trials revealed a 50% reduction in heavy drinking days and an average abstinence rate of 86% over six months post-treatment, compared to 2% before the trial.
Phase 3 trials are currently underway at nine NHS Trusts in the UK, with costs capped at Β£800,000.